Investigative Ophthalmology & Visual Science Cover Image for Volume 64, Issue 8
June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Characteristics of Exudative Age-Related Macular Degeneration without Drusen in Japan Short title: Exudative AMD without Drusen
Author Affiliations & Notes
  • Ichiro Maruko
    Ophthalmology, Tokyo Joshi Ika Daigaku, Shinjuku-ku, Tokyo, Japan
  • Ai Kuranami
    Ophthalmology, Tokyo Joshi Ika Daigaku, Shinjuku-ku, Tokyo, Japan
  • Ruka Maruko
    Ophthalmology, Tokyo Joshi Ika Daigaku, Shinjuku-ku, Tokyo, Japan
  • Mizuha Kakehashi
    Ophthalmology, Tokyo Joshi Ika Daigaku, Shinjuku-ku, Tokyo, Japan
  • Nozomu Hashiya
    Ophthalmology, Tokyo Joshi Ika Daigaku, Shinjuku-ku, Tokyo, Japan
  • Moeko Kawai
    Ophthalmology, Tokyo Joshi Ika Daigaku, Shinjuku-ku, Tokyo, Japan
  • Taiji Hasegawa
    Ophthalmology, Tokyo Joshi Ika Daigaku, Shinjuku-ku, Tokyo, Japan
  • Tomohiro Iida
    Ophthalmology, Tokyo Joshi Ika Daigaku, Shinjuku-ku, Tokyo, Japan
  • Footnotes
    Commercial Relationships   Ichiro Maruko Alcon, Bayer, Canon, Chugai, Nidek, Nikon, Novartis, Santen, Senju, and Topcon, Code I (Personal Financial Interest); Ai Kuranami None; Ruka Maruko None; Mizuha Kakehashi None; Nozomu Hashiya None; Moeko Kawai None; Taiji Hasegawa ayer, Novartis, Alcon, Santen, Kowa, Senju, R E medical, Nikon, JFC, Otsuka and Boehringer Ingelheim, Code I (Personal Financial Interest); Tomohiro Iida Bayer, Novartis, Chugai, and Boehringer Ingelheim, Code C (Consultant/Contractor), AMO, Alcon, Bayer, Canon, HOYA, Nikon, Nidek, Novartis, Otsuka, Pfizer, Santen, Senju, and Topcon, Code I (Personal Financial Interest)
  • Footnotes
    Support  JSPS KAKENHI (Grant Number JP20K09781)
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2163. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ichiro Maruko, Ai Kuranami, Ruka Maruko, Mizuha Kakehashi, Nozomu Hashiya, Moeko Kawai, Taiji Hasegawa, Tomohiro Iida; Characteristics of Exudative Age-Related Macular Degeneration without Drusen in Japan Short title: Exudative AMD without Drusen. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2163.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Although exudative age-related macular degeneration (AMD) is thought to develop with drusen formation, some patients may clinically have macular neovascularization (MNV) cases without drusen.
While the existence of pachychoroid neovasculopathy (PNV) based on choroidal abnormalities without drusen has been proposed, there are cases lacking the characteristics of PNV and also without drusen. In current study, we evaluated the characteristics of patients with exudative AMD without drusen.

Methods : Eighty-six eyes of 84 patients with MNV without drusen (62 males and 22 females, mean age 74.7 years) were included in this study. All patients were Japanese. Subfoveal choroidal thickness (SCT) was measured by optical coherence tomography (Topcon), and response to initial treatment was evaluated by the dry macula rate in patients treated three times during the loading phase with anti-VEGF therapy.

Results : The subjects consisted of 41 eyes in 40 patients with PNV (31 males, 9 females, 73.0 years old) and 45 eyes in 43 patients with MNV (30 males, 13 females, 76.4 years old) neither with features of PNV nor with drusen. Those with polypoidal lesions were 15 (36.6%) and 21 (46.7%) eyes, respectively, which did not reach the difference (P=0.39). The mean SCT tended to be thicker in PNV cases, 302 ± 98 µm and 241 ± 82 µm, respectively, however there was no significant difference (P = 0.12). The dry macula rates just after the loading phase (32 and 39 eyes, respectively) were 87.5% and 53.8%, respectively, which were significantly higher in PNV cases (P<0.01).

Conclusions : There are a certain number of MNV cases without features of PNV and without drusen, and these cases do not respond better to initial treatment with anti-VEGF therapy than PNV cases.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×